Literature DB >> 17431817

Dietary long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria: a randomized controlled trial.

B Koletzko1, T Sauerwald, H Demmelmair, M Herzog, U von Schenck, H Böhles, U Wendel, J Seidel.   

Abstract

BACKGROUND: Pre- and postnatal tissue accretion of long-chain polyunsaturated fatty acids (LCPUFA) has been related to visual and cognitive development in healthy children in several studies. Children with phenylketonuria (PKU) consume diets with very low contents of preformed LCPUFA. We studied prospectively the LCPUFA status in infants with PKU without or with LCPUFA supplementation during the first year of life. SUBJECTS AND METHODS: Infants with PKU were enrolled at diagnosis (<4 weeks of age) and randomized double blind to phenylalanine-free amino acid supplements without LCPUFA (n = 11) or with both arachidonic (AA, 0.46 wt%) and docosahexaenoic acids (DHA, 0.27 wt%) (n = 10). At enrolment and again at 1, 2, 3, 4, 6, 9 and 12 months, plasma phospholipid fatty acids were measured and dietary intakes were calculated from dietary protocols.
RESULTS: Unsupplemented patients showed a marked LCPUFA depletion to levels clearly below those observed in healthy breast-fed infants. In contrast, supplemented infants had stable and higher LCPUFA levels than unsupplemented infants, reaching significant differences for AA values at 3, 4 and 6 months, and for DHA values at 1, 3, 4, 6, 9 and 12 months. Plasma phospholipid levels correlated closely with estimated dietary intakes of preformed LCPUFA.
CONCLUSION: Low LCPUFA intakes with PKU diets induce marked depletion of AA and particularly of DHA in the first year of life. Thus endogenous synthesis of LCPUFA from precursors supplied by diet seems unable to compensate for low LCPUFA intakes. LCPUFA supplementation of PKU diets during the first year of life effectively enhances LCPUFA status to levels comparable to those of healthy breast-fed infants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17431817     DOI: 10.1007/s10545-007-0491-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  31 in total

1.  Global standard for the composition of infant formula: recommendations of an ESPGHAN coordinated international expert group.

Authors:  Berthold Koletzko; Susan Baker; Geoff Cleghorn; Ulysses Fagundes Neto; Sarath Gopalan; Olle Hernell; Quak Seng Hock; Pipop Jirapinyo; Bo Lonnerdal; Paul Pencharz; Hildegard Pzyrembel; Jaime Ramirez-Mayans; Raanan Shamir; Dominique Turck; Yuichiro Yamashiro; Ding Zong-Yi
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-11       Impact factor: 2.839

2.  Polyunsaturated fatty acids and infant visual development: a critical appraisal of randomized clinical trials.

Authors:  R A Gibson; M Makrides
Journal:  Lipids       Date:  1999-02       Impact factor: 1.880

Review 3.  Long-chain polyunsaturated fatty acids in diets for infants: choices for recommending and regulating bodies and for manufacturers of dietary products.

Authors:  B Koletzko; A Sinclair
Journal:  Lipids       Date:  1999-02       Impact factor: 1.880

4.  Fish oil supplementation improves visual evoked potentials in children with phenylketonuria.

Authors:  S Beblo; H Reinhardt; A C Muntau; W Mueller-Felber; A A Roscher; B Koletzko
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

5.  A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants.

Authors:  E E Birch; S Garfield; D R Hoffman; R Uauy; D G Birch
Journal:  Dev Med Child Neurol       Date:  2000-03       Impact factor: 5.449

6.  Effects of a low birthweight infant formula containing human milk levels of docosahexaenoic and arachidonic acids.

Authors:  B Koletzko; S Edenhofer; G Lipowsky; D Reinhardt
Journal:  J Pediatr Gastroenterol Nutr       Date:  1995-08       Impact factor: 2.839

7.  Polyunsaturated fatty acid status in patients with phenylketonuria.

Authors:  P Sanjurjo; L Perteagudo; J Rodríguez Soriano; A Vilaseca; J Campistol
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

8.  Long-chain polyunsaturated fatty acids in plasma and erythrocyte membrane lipids of children with phenylketonuria after controlled linoleic acid intake.

Authors:  A P Pöge; K Bäumann; E Müller; M Leichsenring; H Schmidt; H J Bremer
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

9.  The effects of n-3 and n-6 polyunsaturated fatty acids on plasma lipids and fatty acids of treated phenylketonuric children.

Authors:  C Agostoni; E Riva; G Biasucci; D Luotti; M G Bruzzese; F Marangoni; M Giovannini
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1995-12       Impact factor: 4.006

10.  Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria.

Authors:  Skadi Beblo; Hannes Reinhardt; Hans Demmelmair; Ania C Muntau; Berthold Koletzko
Journal:  J Pediatr       Date:  2007-05       Impact factor: 4.406

View more
  5 in total

Review 1.  Dietary interventions for phenylketonuria.

Authors:  Vanessa J Poustie; Joanne Wildgoose
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

2.  Dietary interventions for phenylketonuria.

Authors:  Elisabeth Jameson; Tracey Remmington
Journal:  Cochrane Database Syst Rev       Date:  2020-07-16

Review 3.  Phenylketonuria: translating research into novel therapies.

Authors:  Gladys Ho; John Christodoulou
Journal:  Transl Pediatr       Date:  2014-04

Review 4.  Long-chain polyunsaturated fatty acids in inborn errors of metabolism.

Authors:  Katalin Fekete; Tamás Decsi
Journal:  Nutrients       Date:  2010-09-15       Impact factor: 5.717

5.  Metabolomics of dietary fatty acid restriction in patients with phenylketonuria.

Authors:  Ulrike Mütze; Skadi Beblo; Linda Kortz; Claudia Matthies; Berthold Koletzko; Mathias Bruegel; Carmen Rohde; Joachim Thiery; Wieland Kiess; Uta Ceglarek
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.